PharmaTimes -
March 2021

This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020. Taking top-spot in the ranking, Exscientia has almost quadrupled its revenue in the last two years, a remarkable achievement and even more so considering the current climate. Turn to page 20 for an in-depth look at the other companies reaching new heights and what’s fuelling their success.

Elsewhere, on page 17, John Pinching and three pharma experts discuss the nature of the relationship between the pharma industry and the NHS and the catalysts for a new dynamic between these two giants of healthcare, while on page 28 the team at Veeva outline their expectations for the life sciences industry in 2021.

We also take another look at the microbiome and the growing realisation of its importance in several disease states and promise in the development of new targeted therapies. On page 38, Anthony Finbow describes how the science of microbiomes will increasingly contribute to research outcomes, while on page 40 Dr Tom Williams provides a close look at the relationship between the microbiome and melanoma.

I hope you enjoy the issue!

Digital edition sponsored by

March 2021 - magazine highlights

Thumbnail image for A stronger connection

A stronger connection

The last decade has brought pharma and the NHS much closer, but while the union is often inspirational, it is also – like any long-term relationship – a bit complicated. Three experts discuss the future of the pharma-NHS dynamic.

Thumbnail image for The Pharma Fast 50

The Pharma Fast 50

PharmaTimes presents Alantra’s annual ranking of the fastest growing private pharma companies in the UK

Thumbnail image for Cash controllers

Cash controllers

Oli Hudson and Steve How, of Wilmington Healthcare, explore how NHS England’s new system-level funding works and the impact on prescribing for high cost drugs

Thumbnail image for A global effort?

A global effort?

COVID-19 threw pharma’s performance on access to medicine into the spotlight. Has the industry passed the test?

Thumbnail image for Hidden impact

Hidden impact

The effect of the COVID-19 pandemic on lung cancer care, and learning lessons from across Europe

Thumbnail image for The missing piece of the puzzle

The missing piece of the puzzle

Supplementing disease modelling with microbiome data is set to enable the life sciences industry to understand more about how drugs interact with different people, and devise more targeted treatments. Anthony Finbow explains how the science of microbiomes will increasingly contribute to pharma research outcomes

Thumbnail image for Smart People: Andrew Meade

Smart People: Andrew Meade

PharmaTimes talks to Andrew Meade, Accenture’s UK and Ireland Life Sciences lead, about the opportunities and challenges triggered by COVID-19 for medicine and digital tech

Thumbnail image for Time for change

Time for change

Why governments need to rethink their regulatory framework in 2021

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download